Vertex Pharmaceuticals
VRTX · NASDAQ
Bulios Fair Price
$372.86
28.2% downside
Current Price
$519.51
According to Bulios Fair Price, VRTX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Vertex Pharmaceuticals (VRTX) is a leading biopharmaceutical company specializing in the development of drugs for the treatment of rare and severe diseases. Their primary focus is on the development of innovative therapies for patients with cystic fibrosis, a genetic disorder affecting the respiratory and digestive systems. Vertex Pharmaceuticals is at the forefront of gene therapy and molecular-based treatments. Vertex Pharmaceuticals stock is suitable for investors interested in the pharmaceutical sector and investments in the treatment of rare diseases. Add Vertex Pharmaceuticals stock to your watchlist on Bulios and be the first to receive updates on new medical breakthroughs and the development of therapies from this prominent company.
Sector
Healthcare
Industry
Biotechnology
CEO
Reshma Kewalramani
Employees
6,400
Headquarters
Boston
Upcoming events
Earnings
Upcoming earnings report